Karen Huppertz

Gene Bridges GmbH specializes in DNA engineering. The firm focuses on market development, product development and innovation of DNA engineering in functional genomics studies and providing customer-specific solutions for DNA engineering projects. Its patented Red/ET Recombination, also known as lambda-red mediated recombination or recombineering, enables cloning and modification of DNA molecules regardless of restriction sites and is useful for the generation of targeting vectors necessary to create transgenic mouse models. The company was founded in 2000 and is headquartered in Heidelberg, Germany.

Cenix BioScience is a contract research organization specialized in combining advanced applications of RNAi with high content phenotypic analyses to enhance and accelerate the discovery and pre-clinical development of novel therapeutics. Cenix has built up a solid track record, successfully advancing therapeutic programs for numerous major industry and academic partners by addressing the specific needs of each through fully-customized, cutting-edge research offerings covering a wide range of disease fields. The well-established core capabilities in high throughput RNAi and multi-parametric microscopy assays have yielded optimized protocols in a broad and ever-growing collection of cultured cell models, and are now complemented by microRNA-focused experimentation and in vivo applications of synthetic siRNAs. As such, Cenix is a mature and fully-proven industrial research provider, applying the highest of scientific best practices and offering a breadth and depth of expertise second to none world wide